Skip to main content

Table 8 Adverse events following addition of carboplatin/gemcitabine combination as second-line NACT in the “intervention” group

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Anemia 10 (40) 10 (40)
ALT rise 10 (40) 7 (28) 1 (4)
AST rise 8 (32) 2 (8)
ALP rise 5 (20)
Neutropenia (↓ANC) 6 (24) 7 (28) 3 (12)
Leukopenia 13 (52) 4 (16) 2 (8)
Thrombocytopenia 10 (40) 1 (4) 1 (4)
Oral mucositis 1 (4)
  1. ALT alanine amino transferase, AST aspartate amino transferase, ALP alkaline phosphatase, ANC absolute neutrophil count